发明名称 EP4 RECEPTOR SELECTIVE AGONIST IN TREATMENT OF OSTEOPOROSIS
摘要 PROBLEM TO BE SOLVED: To provide a method that comprises administering a prostaglandin agonist which is useful for preventing the decrease of bone, recovering or increasing the quantity of the bone, and promoting bone recovery including the treatments of states showing low bone quantity and/or bone defect in vertebrates, especially mammals including human being, and to provide a medicinal composition containing the prostaglandin agonist. SOLUTION: This method for treating a state showing a low bone quantity, especially osteoporosis, infirmitas, osteoporotic fracture, bone deficiency, idiopathic bone decrease of infant, alveolar bone decrease, mandible bone decrease, fracture, osteectomy, bone decrease related to periodontitis, or prothesis inner growth, comprising administering a prostaglandin agonist which is an EP4 receptor selective prostaglandin agonist. The EP4 receptor selective prostaglandin agonist is especially a compound of formula I (variables are as defined in the specification).
申请公布号 JP2001181210(A) 申请公布日期 2001.07.03
申请号 JP20000390594 申请日期 2000.12.22
申请人 PFIZER PROD INC 发明人 CAMERON KIMBERLY O'KEEFE;KE HAUZHU;BRUCE ALLEN REFUKAA;THOMPSON DAVID DUANE
分类号 A61K;A61K31/4015;A61K31/4025;A61K31/41;A61K31/5575;A61K45/00;A61P19/00;A61P19/10;A61P43/00;C07D;C07D207/26;C07D207/27;C07D403/06;(IPC1-7):A61K45/00;A61K31/401 主分类号 A61K
代理机构 代理人
主权项
地址